Results 141 to 150 of about 169,585 (295)

Cost-Offsets of New Medications for Treatment of Schizophrenia [PDF]

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia.
Richard G. Frank, Sharon-Lise Normand, Thomas G. McGuire   +2 more
core  

Association of Preoperative Depression and Clinical Outcomes After Head and Neck Free Flap Reconstruction

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Comorbid depression is a significant negative predictor of survival in patients with head and neck cancer (HNC). Prior studies have shown a prevalence of up to 40.1%; however, depression is often underdiagnosed in this patient population. Study Design Retrospective cohort. Setting Single‐institution database.
Sindhura Sridhar, Daniel P. Larson, Brooke B. Swain, Heezy Suh, Daniel R. S. Habib, Kelly Vittetoe, Donald Sengstack, Michael C. Topf, Melanie D. Hicks   +8 more
wiley   +1 more source

Editorial: Safety and side effects of psychotropic medications, volume III

Frontiers in Psychiatry
Renato de Filippis, Mireia Solerdelcoll, Mireia Solerdelcoll, Mohammadreza Shalbafan, Mohammadreza Shalbafan   +4 more
doaj   +1 more source

Combining dance movement therapy and pharmacotherapy in adolescents with major depressive disorder: A randomized controlled study

Pediatric Investigation, EarlyView.
The current study was among the first clinical trials that combined dance movement therapy (DMT) and pharmacotherapy to enhance self‐esteem and alleviate anxious and depressive symptoms in adolescents with major depressive disorder. Results indicated that DMT combined with pharmacotherapy improved depression symptoms more than pharmacotherapy alone ...
Yanru Liu, Wanling Zhang, Xuejiao Sun, Xiaoxuan Fan, Na Hu, Xuanzi Zhou, Xiao Leng, Ying Li   +7 more
wiley   +1 more source

Trends in use of antipsychotics in Germany 2014-2024: a nationwide population-based study. [PDF]

BMC Psychiatry
Espinosa Daudí A, Kieble M, Schulz M.
europepmc   +1 more source

Medication prescription patterns in cancer rehabilitation physiatry outpatients: A multicenter retrospective study

PM&R, EarlyView.
Abstract Background and Objective Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine.
Matthew Chen, Nafis Eghrari, David Leong, Philip Chang, Jasmine Zheng, Amy Ng, Richard Wilson, Mary Vargo   +7 more
wiley   +1 more source

Understanding the factors influencing antipsychotic medication use in continuing care during the COVID-19 pandemic: a qualitative descriptive study. [PDF]

BMJ Open
Karimi-Dehkordi M, Asaana P, Wagg A, Hanson HM, Harasym P.   +4 more
europepmc   +1 more source

Is antipsychotic medication stigmatizing for people with mental illness? [PDF]

, 2009
Jenkins, Janis H, Sajatovic, Martha
core  

Early Cervical and Orofacial Variable Dystonia in Levodopa‐Naïve PRKN Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Amy Gallagher, Aine Redmond, John McKinley, John Inocentes, Diana A Olszewska, Conor Fearon, Tim Lynch   +6 more
wiley   +1 more source

Safety of 8‐Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi‐Center, Double‐Blinded, Placebo‐Controlled Study

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha (Withania somnifera) has been recognized for enhancing physical strength, mental well‐being, and overall vitality. Despite its long‐standing use across generations, some clinical reports have noted occasional adverse events. This study compared the safety and tolerability of Ashwagandha Root Extract (ARE) in healthy adults.
Ketan Pakhale, Jaising Salve, John Ademola, Jose Parraca, Deepak Langade   +4 more
wiley   +1 more source